News & Commentary

Provaré Technology Completes First Task for Theragenics

Alpharetta, GA, February 18, 2005 — Provaré Technology completes its first task for Theragenics Corporation (NYSE: TGX) today, validating a new and very complex piece of automated manufacturing equipment with just 128 hours of effort. The effort, which began just after the new year, involved clarification of requirements, development of a test plan, development of a test protocol, and generation of a list of recommended corrective actions. It was Provaré Technology’s first experience with manufacturing equipment and with adherence to FDA regulations.

“This project was new and different for us, but turned out to be very well suited to our strengths,” says Bill Tepper, CEO of Provaré Technology. “It was a challenge, yes, but a very inspiring one. I am thrilled to have been able to help bring new life saving treatments to the market faster and look forward to working with Theragenics in the future.”

“Bill and Provaré were not our cheapest per hour option for this task,” says Len Owens, Director of Quality at Theragenics, “but I had a feeling they brought the best value proposition to the table. And boy was I ever right! Bill hit the ground running and never looked back. I won’t hesitate to call on Provaré Technology when I need help again.”

According to Tepper, medical device manufacturing will be an area of focus for Provaré Technology in the near future. “I have always believed that we have a lot to offer any technology company that is subject to FDA regulations,” says Tepper. “And I think this success has given us some needed credibility in this area. I look forward to more challenges even harder than this one.”

Founded in 2004, Provaré Technology is a provider of a variety of services crucial to the development of technology products. Provaré’s offerings include software testing services, configuration management (CM) services, development process improvement consulting, recruiting and training of test and CM staff members, etc. Provaré staff members have a combined 68 years of experience spanning all aspects of technology product development for space, defense, intelligence, telecom, wireless, point-of-sale, data warehousing, cable video, and internet access industries. Provaré now adds medical device manufacturing to its portfolio. For more information about products and services offered by Provaré Technology, please visit www.Provaré.com.

Theragenics Corporation® is committed to being a leading provider of brachytherapy treatment devices for prostate cancer and other degenerative disease states. The Company is the manufacturer and marketer of the palladium-103 device TheraSeed® and I-Seed, an iodine-125 based device. Both devices are used in the treatment of localized prostate cancer in one-time, minimally invasive procedures. Theragenics™ is the world’s largest producer of palladium-103 and is involved in research and development utilizing palladium-103 and other isotopes for the treatment of a wide variety of diseases, including macular degeneration. For additional information on the Company, call Theragenics™ Investor Relations Department at (800) 998-8479. The Company’s common stock is traded on the New York Stock Exchange under the symbol TGX. Additional information can be found on the Company website:


Bill Tepper, CEO
Provaré Technology
Phone: +1 (770) 814-4169

Len Owens, Director of Quality
Theragenics Corporation
Phone: +1 (770) 831-4184

z-lib zlib login